Overview

Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2026-04-30

Target enrollment:

Participant gender:

Summary

This study is to evaluate the tolerability and safety of ONO-7475 in combination with osimertinib in the first-line treatment of patients with EGFR-mutated, stage IIIB/IIIC/IV or recurrent non-small cell lung cancer (NSCLC), which is unsuitable for radical irradiation.

Phase:

PHASE1

Details

Lead Sponsor:

Ono Pharmaceutical Co. Ltd

Treatments:

osimertinib